|
1
|
Losina E, Walensky RP, Geller A,
Beddingfield FC III, Wolf LL, Gilchrest BA and Freedberg KA: Visual
screening for malignant melanoma: A cost-effectiveness analysis.
Arch Dermatol. 143:21–28. 2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rigel D: Cutaneous ultraviolet exposure
and its relationship to the development of skin cancer. J Am Acad
Dermatol. 58 (Suppl 2)(S129-S132)2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Food and Drug Administration: Consumer
health information November 2009. Available at: uriwww.fda.gov/consumer.https://www.fda.gov/consumer.
Accessed Feb 18, 2010.
|
|
4
|
Candido S, Rapisarda V, Marconi A,
Malaponte G, Bevelacqua V, Gangemi P, Scalisi A, McCubrey JA,
Maestro R, Spandidos DA, et al: Analysis of the B-RafV600E mutation
in cutaneous melanoma patients with occupational sun exposure.
Oncol Rep. 31:1079–1082. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gandini S, Sera F, Cattaruzza MS, Pasquini
P, Picconi O, Boyle P and Melchi CF: Meta-analysis of risk factors
for cutaneous melanoma: II, Sun exposure. Eur J Cancer. 41:45–60.
2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Elwood JM and Jopson J: Melanoma and sun
exposure: An overview of published studies. Int J Cancer.
73:198–203. 1997.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ehrsam E, Kallini JR, Lebas D, Khachemoune
A, Modiano P and Cotten H: Fully regressive melanoma - a case
without metastasis. J Clin Aesthet Dermatol. 9:42–46.
2016.PubMed/NCBI
|
|
8
|
Smoller BR: Histologic criteria for
diagnosing primary cutaneous malignant melanoma. Mod Pathol. 19
(Suppl 2)(S34-S40)2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zurac S, Negroiu G, Petrescu S, Andrei R,
Tebeica T, Popp C, Musţată R, Neagu M, Constantin C, Solovan C, et
al: Spectrum of morphologic alterations of regression in cutaneous
melanoma - potential for improving disease prognosis. Rom J Intern
Med. 50:145–153. 2012.PubMed/NCBI
|
|
10
|
Aung PP, Nagarajan P and Prieto VG:
Regression in primary cutaneous melanoma: Etiopathogenesis and
clinical significance. Lab Invest. 97:657–668. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gugger A, Barnhill RL, Seifert B, Dehler
S, Moch H, Lugassy C, Marques-Maggio E, Rushing EJ and Mihic-Probst
D: Cutaneous melanoma with brain metastasis: Report of 193 patients
with new observations. PLoS One. 11(e0156115)2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Printz C: Spontaneous regression of
melanoma may offer insight into cancer immunology. J Natl Cancer
Inst. 93:1047–1048. 2001.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wenzel J, Bekisch B, Uerlich M, Haller O,
Bieber T and Tüting T: Type I interferon-associated recruitment of
cytotoxic lymphocytes: A common mechanism in regressive melanocytic
lesions. Am J Clin Pathol. 124:37–48. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Håkansson A, Gustafsson B, Krysander L,
Hjelmqvist B, Rettrup B and Håkansson L: Expression of ICAM-1
during IFN-alpha-based treatment of metastatic malignant melanoma:
Relation to tumor-infiltrating mononuclear cells and regressive
tumor changes. J Interferon Cytokine Res. 19:171–177.
1999.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lupu M, Caruntu A, Caruntu C, Papagheorghe
LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki
M, et al: Neuroendocrine factors: The missing link in non melanoma
skin cancer (Review). Oncol Rep. 38:1327–1340. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sandru F, Popa A and Dumitrascu MC:
Dermoscopic view of vertical growth phase nodular malignant
melanoma. Med Image Database. 2:35–36. 2019. View Article : Google Scholar
|
|
17
|
Caruntu C, Boda D, Constantin C, Caruntu A
and Neagu M: Catecholamines increase in vitro proliferation of
murine B16F10 melanoma cells. Acta Endocrinol (Copenh). 10:545–558.
2014. View Article : Google Scholar
|
|
18
|
Boda D: Cellomics as integrative omics for
cancer. Curr Proteomics. 10:237–245. 2013. View Article : Google Scholar
|
|
19
|
Bories N, Dalle S, Debarbieux S, Balme B,
Ronger-Savlé S and Thomas L: Dermoscopy of fully regressive
cutaneous melanoma. Br J Dermatol. 158:1224–1229. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Prodea MC, Sandru F, Carpenco E, Gaje PN,
Horhat ID, Ceausu AR, Mederle N and Mederle OA: A rare sweat gland
tumour-immunohistochemical features. Rev Chim (Bucharest).
70:1863–1865. 2019. View Article : Google Scholar
|
|
21
|
Ilie MA, Caruntu C, Lupu M, Lixandru D,
Tampa M, Georgescu SR, Bastian A, Constantin C, Neagu M, Zurac SA,
et al: Current and future applications of confocal laser scanning
microscopy imaging in skin oncology. Oncol Lett. 17:4102–4111.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Stefan O, Tudor G, Constantinescu C, Luca
C, Boda D, Caruntu C, Cioplea M, Nichita L and Zurac SA: E-cadherin
and N-cadherin expression pattern in common melanocytic nevi.
Virchows Arch. 475(S28-S28)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Neagu M, Constantin C, Tanase C and Boda
D: Patented biomarker panels in early detection of cancer. Recent
Pat Biomark. 1:10–24. 2011. View Article : Google Scholar
|
|
24
|
Zurac S, Neagu M, Constantin C, Cioplea M,
Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et
al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in
cutaneous melanoma with regression and their possible function as
prognostic predictors. Oncol Lett. 11:3354–3360. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Diaconeasa A, Boda D, Solovan C, Enescu
DM, Vîlcea AM and Zurac S: Histopathologic features of Spitzoid
lesions in different age groups. Rom J Morphol Embryol. 54:51–62.
2013.PubMed/NCBI
|
